15/02/2010[Company watch]Parexel International experienced a strong growth in demand

Meanwhile, another Boston area company, Parexel International a clinical stage CRO, has experienced a strong growth in demand for its services in China. The company has upped its headcount to 1,600 from 1,000 just two years ago, its business coming from multinational big pharmas.

Meanwhile, another Boston area company, Parexel International a clinical stage CRO, has experienced a strong growth in demand for its services in China. The company has upped its headcount to 1,600 from 1,000 just two years ago, its business coming from multinational big pharmas. According to the company, the major advantage to doing trials in China is the large treatment-naive population that reduces the time to sign up patients.
â€śPatient recruitment is the leading cause of delays in clinical trials. It is much quicker to attract patients in China, because access to top-notch care is limited there. Itâ€™s also easier to find patients that arenâ€™t currently on any therapy,â€ť said Mark Goldberg, CEO of Parexel. That is one of the reasons that conducting a clinical trial in China reduces by 50% the cost of performing a trial there.